The carboxypeptidase B1 (CPB1) antibody is a tool used to detect and study CPB1. a zinc-dependent metalloprotease enzyme encoded by the *CPB1* gene in humans. CPB1 belongs to the carboxypeptidase family, which cleaves C-terminal basic amino acids (arginine or lysine) from proteins and peptides. It is primarily synthesized in the pancreas as an inactive zymogen (pro-CPB1) and activated in the small intestine, where it aids in digesting dietary proteins. Beyond digestion, CPB1 is implicated in diverse physiological processes, including inflammation, tissue repair, and hormone processing.
CPB1 antibodies are widely utilized in research to investigate the enzyme's expression, localization, and function in health and disease. For example, elevated CPB1 levels have been observed in conditions like acute pancreatitis, colorectal cancer, and metabolic disorders, suggesting its potential role as a biomarker or therapeutic target. These antibodies enable techniques such as Western blotting, immunohistochemistry, and ELISA to assess CPB1 expression patterns in tissues or biofluids.
Recent studies also explore CPB1's involvement in tumor progression, particularly in modulating extracellular matrix remodeling and immune responses. Additionally, CPB1 antibodies contribute to structural studies, helping elucidate its catalytic mechanism and interactions with inhibitors. Commercial CPB1 antibodies are typically validated for specificity, often targeting epitopes in the mature enzyme or propeptide regions. Continued research with CPB1 antibodies may deepen insights into its pathophysiological roles and clinical applications.